Showing results (301-310 of 584) with videos related to
Sort By:
Pageof 59
Lung Cancer (Amsterdam, Netherlands)|September 15, 2019
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group surveyAntonin Levy, Lizza E L Hendriks, Cécile Le Péchoux, et al.The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2015
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced ToxicitiesHenrik Gréen, Johanna Hasmats, Ilya Kupershmidt, et al.International Journal of Radiation Oncology, Biology, Physics|March 16, 2026
Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trialWael S Zrafi, Víctor Albarrán-Artahona, Filippo G Dall'Olio, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 17, 2019
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid TumorsPatrick Robelin, Julien Hadoux, Julien Forestier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?Jordi Remon, Martina Bortolot, Paolo Bironzo, et al.European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 26, 2014
Is sacrifying the phrenic nerve during thymoma resection worthwhile?Sarah Hamdi, Olaf Mercier, Elie Fadel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2023
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung CancerAlban Bessede, Florent Peyraud, Benjamin Besse, et al.Molecular Cancer Therapeutics|October 9, 2021
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant MutationsBrion W Murray, Evan Rogers, Dayong Zhai, et al.European Journal of Cancer (Oxford, England : 1990)|April 21, 2024
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockersPierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, et al.Pageof 59